Now Approved in the U.S.
Our Science and Technology
Rooted in a Deep Understanding of Genetics
The genetic basis of human disease continues to inspire our science and technology as we expand to new therapeutic approaches, while our industry-leading chemistry helps us target the right medicine to the right disease – providing a rich source for future breakthroughs and transformative impact.
WHO WE ARE
Ionis unites groundbreaking science and technology with relentless passion to discover and deliver medicines that enable better futures for people living with serious diseases.
Our commitment to changing lives is a calling that pushes us to deliver the next solution for patients and those who care for them.
We have set our sights on providing new solutions across the spectrum of diseases, from common intractable neurologic conditions to cardiometabolic disorders and select areas of high patient needs.
We push beyond the impossible to unleash the potential of patients – and those who care for them – enabling them to make their own impact on the world.
We believe operating responsibly and sustainably creates long-term value and a positive impact for our company, stakeholders, patients, communities and the broader world.
JOIN OUR TEAM
Seizing the Moment to Unlock the Potential of RNA- and DNA-Targeted Medicines
If you’re driven to deliver on the promise of groundbreaking medicines that empower patients and caregivers to make their own impact on the world, come join us.
LATEST NEWS FEED
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
– Despite currently available treatment options, the majority of surveyed adults with HAE reported making tradeoffs in their daily lives due to the unexpected and unpredictable nature of HAE attacks – – Opportunity exists for more consistent use of tools to support transparent communications
Ionis to hold first quarter 2025 financial results webcast
Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 16, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30 th at 11:30 a.m.
Ionis to host expert panel discussion on sHTG
– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET – CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 3, 2025-- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
– Despite currently available treatment options, the majority of surveyed adults with HAE reported making tradeoffs in their daily lives due to the unexpected and unpredictable nature of HAE attacks – – Opportunity exists for more consistent use of tools to support transparent communications
Ionis to hold first quarter 2025 financial results webcast
Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 16, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30 th at 11:30 a.m.
Ionis to host expert panel discussion on sHTG
– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET – CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 3, 2025-- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet
Sign Up for News Alerts
For the latest on Ionis news and developments
<p>– Despite currently available treatment options, the majority of surveyed adults with HAE reported making tradeoffs in their daily lives due to the unexpected and unpredictable nature of HAE attacks – – Opportunity exists for more consistent use of tools to support transparent communications</p>
Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 16, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30 th at 11:30 a.m.
– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET – CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 3, 2025-- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet
Click here to read an important notice about a cybersecurity incident relating to services provided to WEX Health (an Ionis employee benefits plan administrator).